Mechanisms of tumour progression

Coordinator: Xosé Bustelo/ Co-coordinator: Anna Bigas

Tumour progression is a highly complex process in which a large number of genes and molecular mechanisms are involved. Understanding how these mechanisms contribute to the development and malignisation of tumours is one of the greatest challenges faced by today’s oncology. An explanation of these processes is vital to understand the basis of cancer, develop better diagnostic tools and identify therapeutic targets with which to combat this more effectively.

The CIBERONC Programme for Mechanisms of Tumour Progression combines the efforts of 11 leading research groups in their field at the same centre. By using bioinformatic and experimental research resources, this enables learning more about the elements and biological programmes which are a key factor in the origin, evolution and malignisation (resistance to drugs, metastases) of the most epidemiologically-relevant tumours in Spanish population. On this basis it is hoped to develop new channels to be used for better diagnosis and treatment of patients.

Lines of research:

  • Identification of early tumour-promoting mutations and signal modifiers linked with the origin and progression of tumours and response to therapy.
  • Biological validation of the candidate genes/programmes identified as causal contributors to the disease.
  • Exploitation of genes and candidate routes for development of precision medicine.

Groups:

Main ResearcherConsortium InstitutionRegions
Xosé R. Bustelo Centro de Investigación del Cáncer Castilla y León
Anna Bigas Hospital del Mar Cataluña
Jesús M. Paramio Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas Madrid
Carlos López Otín Universidad de Oviedo Asturias
Alberto Muñoz Instituto de Investigación Alberto Sols Madrid
Pilar Santisteban Instituto de Investigación Alberto Sols Madrid
Eugenio Santos Centro de Investigación del Cáncer Castilla y León
Francisco J. Oliver Instituto de Parasitología y Biomedicina López Neyra Andalucía
Piero Crespo Instituto de Biomedicina y Biotecnología de Cantabria Cantabria
Arkaitz Carracedo BIOGUNE País Vasco
Joan Seoane Instituto de Investigación Oncológica Vall d'Hebron Cataluña